<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - TOBRAMYCIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>TOBRAMYCIN</h1>

        <p><a href="../drugClass/PHP34544.html">AMINOGLYCOSIDES</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Local treatment of infections</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply twice daily for 6&#8211;8 days.</li>
              <li class="dose child"><strong>For children 1&#8211;17 years</strong><br/>
                Apply twice daily for 6&#8211;8 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Local treatment of infections (severe infection)</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.</li>
              <li class="dose child"><strong>For children 1&#8211;17 years</strong><br/>
                Apply 4 times a day for first day, then apply twice daily for 5&#8211;7 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Septicaemia</span>,
                <span class="indication">Meningitis and other CNS infections</span>,
                <span class="indication">Biliary-tract infection</span>,
                <span class="indication">Acute pyelonephritis or prostatitis</span>,
                <span class="indication">Pneumonia in hospital patients</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                3 mg/kg daily in 3 divided doses; increased if necessary up to 5 mg/kg daily in 3&#8211;4 divided doses, increased dose used in severe infection; dose to be reduced back to 3 mg/kg as soon as clinically indicated.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Urinary-tract infection</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2&#8211;3 mg/kg for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Chronic <ph outputclass="organism"> <i>Pseudomonas aeruginosa</i> </ph> infection in patients with cystic fibrosis</span>,
            </h4>
            <p class="specificity"><span class="route">By inhalation of powder</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                112 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin inhalation powder.</li>
            </ul>
          </section>
        </section>
        
        
        
            <section class="extremesOfBodyWeight">
                <h3>Doses at extremes of body-weight</h3>
              <p>To avoid excessive dosage in obese patients, use ideal weight for height to calculate parental dose and monitor serum-tobramycin concentration closely.</p>
            </section>
        
        
      </section>







      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>uncommon:</strong> rash in adults, rash,
              </p>
              <p>
                <strong>notKnown:</strong> bronchospasm, cough (more frequent by inhalation of powder), dysphonia, epistaxis, haemoptysis, laryngitis, mouth ulcers, pharyngitis, salivary hypersecretion, taste disturbances,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, dilute with Glucose 5% or Sodium Chloride 0.9%; give over 20&#8211;60 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Nebcin</i>
            <tm tmtype="reg"/>); intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%.</p><p>For adult intermittent infusion suggested volume 50&#8211;100&#8239;mL given over 20&#8211;60 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Other inhaled drugs should be administered before tobramycin.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Patient counselling is advised for Tobramycin dry powder for inhalation (administration).</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA276</h3>
              <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph> </p> <p outputclass="title">Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)</p> <p>Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by <ph outputclass="organism"> <i>Pseudomonas aeruginosa</i> </ph> in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contra-indications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.</p> <p>Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.</p><xref format="html" href="http://www.nice.org.uk/TA276">www.nice.org.uk/TA276</xref>
                <a href="http://www.nice.org.uk/TA276" target="_blank">www.nice.org.uk/TA276</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by inhalation:</strong>
            severe haemoptysis&#8212;risk of further haemorrhage
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>
            <i>Extended interval dose regimen in neonates</i>: pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>
            <i>Once daily dose regimen</i>: pre-dose (&#8216;trough&#8217;) concentration should be less than 1&#8239;mg/litre.</p><p>
            <i>Multiple daily dose regimen</i>: one-hour (&#8216;peak&#8217;) serum concentration should not exceed 10&#8239;mg/litre (8&#8211;12&#8239;mg/litre in cystic fibrosis); pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>One-hour (&#8216;peak&#8217;) serum concentration should not exceed 10&#8239;mg/litre; pre-dose (&#8216;trough&#8217;) concentration should be less than 2&#8239;mg/litre.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">When used by <ph outputclass="route">inhalation</ph></h3>
              <p>Measure lung function before and after initial dose of tobramycin and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using bronchodilator.</p><p>Monitor renal function before treatment and then annually.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or when used by <ph outputclass="route">inhalation</ph> in children</h3>
              <p>Local guidelines may vary in dosing advice provided.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of TOBRAMYCIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,

            <div id="PHP75687"><a href="../medicinalForm/PHP75687.html" data-target="#PHP75687" data-action="load">Solution for injection</a></div>
            <div id="PHP75716"><a href="../medicinalForm/PHP75716.html" data-target="#PHP75716" data-action="load">Inhalation powder</a></div>
            <div id="PHP75709"><a href="../medicinalForm/PHP75709.html" data-target="#PHP75709" data-action="load">Nebuliser liquid</a></div>
            <div id="PHP75702"><a href="../medicinalForm/PHP75702.html" data-target="#PHP75702" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
